- P-ISSN 1225-0163
- E-ISSN 2288-8985
- P-ISSN1225-0163
- E-ISSN2288-8985
- SCOPUS, ESCI, KCI
Article Detail
Home > Article Detail
Identification and evaluation of fragmentation pathways of PDE-5 inhibitor analogues using LC-QTOF-MS
Analytical Science and Technology / Analytical Science and Technology, (P)1225-0163; (E)2288-8985
2015, v.28 no.4, pp.278-287
https://doi.org/10.5806/AST.2015.28.4.278
&
(2015). Identification and evaluation of fragmentation pathways of PDE-5 inhibitor analogues using LC-QTOF-MS. Analytical Science and Technology, 28(4), 278-287, https://doi.org/10.5806/AST.2015.28.4.278
- Downloaded
- Viewed
Abstract
Phosphodiesterase type 5 inhibitors (PDE-5 inhibitors) are used in the treatment of erectile dysfunction. In recent years, a number of reports have been conducted on dietary supplements contaminated with PDE-5 analogues. In this study, 58 analogues of PDE-5 inhibitors were sorted into five groups: tadalafil, sildenafil, hongdenafil, vardenafil, and other analogues. These analogues were then evaluated using a liquid chromatographyquadrupole- time of flight mass spectrometry (LC-QTOF-MS) electrospray ionization mass method. Each compound has a unique fragmentation ion, which can be easily analyzed qualitatively. The fragmentation pathways of the analogues were elucidated based on the QTOF-MS and MS/MS data. Common ions were confirmed for each group by analyzing the structural characteristics and fragmentation pathways. Specifically, common ions were observed at m/z 169.08 and 135.04 (tadalafil analogues), m/z 311.15 and 283.12 (sildenafil analogues and hongdenafil analogues), and m/z 312.16 and 151.09 (vardenafil analogues). The advantage of this method is that the structure of unknown components can be determined by interpreting the product ions. Hence, the developed method can be used for the identification of unknown compounds. Fragmentation pathways may also aid in the detection and identification of PDE-5 inhibitor analogues.
- keywords
- PDE-5, LC-QTOF-MS, fragmentation pathway, identification, unknown compounds
Reference
1
1. B. J. Venhuis, G. Zomer, M. Hamzink, H. D. Meiring, Y. Aubin and D. de Kaste, J. Pharm. Biomed. Anal., 54(4), 735-741 (2011).
2
2. L. Blok-Tip, B. Zomer, F. Bakker, K. D. Hartog, M. Hamzink, J. Ten Hove, M. Vredenbregt, D. de Kaste, Food Addit. Contam., 21(8), 737-748 (2004).
3
4. Q. Liang, J. Qu, G. Luo and Y. Wang, J. Pharm. Biomed. Anal., 40(2), 305-311 (2006).
4
5. S. R. Gratz, C. L. Flurer and K. A. Wolnik, J. Pharm. Biomed. Anal., 36(3), 525-533 (2004).
5
6. M. H. Shin, M. K. Hong, W. S. Kim, Y. J. Lee and Y. C. Jeoung, Food Addit. Contam., 20(9), 793-798 (2003).
6
7. R. Yuan and Y. Lin, Pharmacol. Ther., 86(2), 191-198 (2000).
7
8. FDA approves Stendra for erectile dysfunction, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302140.htm/, Assessed 13 Jan 2001.
8
9. O. Shaeer. The Global Online Sexuality Survey (GOSS): The United States of America in 2011 Chapter II: phosphodiesterase inhibitors utilization among English speakers. J. Sex. Med., 10(2), 532-540 (2012).
9
10. A. W. Shindel. Update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J. Sex. Med., 6, 2352-2364 (2009).
10
11. C. G. Stief, S. Uckert, A. J. Becker, M. C. Truss and U. Jonas, J. Urol., 159(4), 1390-1393 (1998).
11
12. B. J. Venhuis and D. Kaste, J. Pharm. Biomed. Anal., 69, 196-208 (2012).
12
13. M. Y. Low, Y. Zeng, L. Li, X. W. Ge, R. Lee and B. C. Bloodworth, H. L. Koh, Drug Saf., 32(12), 1141-1146 (2009).
13
13. Illicit erectile dysfunction products in the Netherlands http://www.rivm.nl/Documenten_en_publicaties/Wetenschappelijk/Rapporten/2011/september/Illicit_erectile_dysfunction_products_in_the_Netherlands_A_decade_of_trends_and_a_2007_2010_product_update/,Assessed 8 Sept 2011.
14
14. M. Sugita and M. Miyakawa, Health Preventive Med., 15(4), 244-251 (2010).
15
15. S. Singh, B. Prasad, A. A. Savaliya, R. P. Shah and V. M. Gohil, A. Kaur, Trends Anal. Chem., 28(1), 13-28 (2009).
16
16. J. B. Guo, Y. Xu, Z. B. Huang, Q. H. He, S. W. Liu, Anal. Chim., 658(2), 197-203 (2010).
17
17. S. M. Khalil, Microchim., 158, 233-238 (2007).
18
18. C. M. Gryniewicz, J. C. Reepmeyer, J. F. Kauffman and L. F. Buhse, J. Pharm. Biomed. Anal., 49(3), 601-606 (2009).
19
19. D. J. Mans, R. J. Callahan, J. D. Dunn and C. M. Gryniewicz-Ruzicka, J. Pharm. Biomed. Anal., 75(5), 153-157 (2013).
20
20. D. Z. Mao, X. X. Weng and Y. J. Yang, J. Raman Spectrosc., 43(12), 1985-1990 (2012).
21
21. C. L. Cheng, G. J. Kang and C. H. Chou, J. Chromatogr., 1154(1-2), 222-229 (2007).
22
22. M. Park and S. Ahn, J. Forensic Sci., 57(6), 1637-1640 (2012).
23
23. P. Y. Sacre, E. Deconinck, P. Chiap, J. Crommen, F. Mansion, E. Rozet, P. Courselle and J. O. De Beer, J. Chromatogr., 1218(37), 6439-6447 (2011).
24
24. C. N. Man, N. M. Noor and R. Lajis, J. Chromatogr., 1218(39), 7055-7060 (2011).
25
25. P. Nikolaou, I. Papoutsis, S. Athanaselis, G. Alevisopoulos, A. Khraiwesh, C. Pistos and C. Spiliopoulou, J. Pharm. Biomed. Anal., 56(3), 577-581 (2011).
26
26. R. Patterson, P. Mabe, E. N. Mitchell and W. Cory, Forensic Sci. Int., 222(1-3), 83-88 (2012).
27
27. C. S. Ng, T. Y. Law, Y. K. Cheung, P. C. Ng and K. K. Choi, Anal. Methods., 2, 890-896 (2010).
28
28. Y. Ren, C. S. Wu and J. L. Zhang, J. Sep. Sci., 35(21), 2847-2857 (2012).
29
29. M. E. Hadwiger, M. L. Trehy, W. Ye, T. Moore, J. Allgire and B. Westenberger, J. Chromatogr. A., 1217(48), 7547-7555 (2010).
30
30. Y. Cai, T. G. Cai, Y. Shi, X. L. Cheng, L. Y. Ma, S. C. Ma, R. C. Lin and W. Feng, J. Liq. Chromatogr. Rel. Technol., 33, 1287-1306 (2010).
31
31. A. Lanzarotta, J. B. Crowe, M. Witkowski and B. M. Gamble, J. Pharm. Biomed. Anal., 67-68, 22-27 (2012).
32
32. F. W. McLafferty. Interpretation of Mass Spectra, third edition. University Science Books, p 51-215, Mill Valley, California, 1980.
33
33. J. H. Lee, H. J. Kim, E. Noh, J. Y. Kim, S. H. Cho, J.-A Do, C.-Y. Yoon, S. Cho and W. S. Kim, J. Pharm. Biomed. Anal., 103, 80-84 (2015).
Other articles from this issue
- Spectrofluorimetric determination of trace Co(II) in aqueous samples with quinalizarin-β-cyclodextrin inclusion complex
- Inhibitory effect of Angelica gigas extract powder on induced inflammatory cytokines in rats osteoarthritis
- QSPR model for the boiling point of diverse organic compounds with applicability domain
- Identification and evaluation of fragmentation pathways of PDE-5 inhibitor analogues using LC-QTOF-MS
- A study on the distribution of glitter particles from an university building
- Determination of streptomycin in kiwifruit samples using LC-ESI-MS/MS
- more
Recommanded Articles
This website recommended the use the Chrome browser for journal website.